Back to Search Start Over

Small Molecule Targets TMED9 and Promotes Lysosomal Degradation to Reverse Proteinopathy.

Authors :
Dvela-Levitt M
Kost-Alimova M
Emani M
Kohnert E
Thompson R
Sidhom EH
Rivadeneira A
Sahakian N
Roignot J
Papagregoriou G
Montesinos MS
Clark AR
McKinney D
Gutierrez J
Roth M
Ronco L
Elonga E
Carter TA
Gnirke A
Melanson M
Hartland K
Wieder N
Hsu JC
Deltas C
Hughey R
Bleyer AJ
Kmoch S
Živná M
Barešova V
Kota S
Schlondorff J
Heiman M
Alper SL
Wagner F
Weins A
Golub TR
Lander ES
Greka A
Source :
Cell [Cell] 2019 Jul 25; Vol. 178 (3), pp. 521-535.e23.
Publication Year :
2019

Abstract

Intracellular accumulation of misfolded proteins causes toxic proteinopathies, diseases without targeted therapies. Mucin 1 kidney disease (MKD) results from a frameshift mutation in the MUC1 gene (MUC1-fs). Here, we show that MKD is a toxic proteinopathy. Intracellular MUC1-fs accumulation activated the ATF6 unfolded protein response (UPR) branch. We identified BRD4780, a small molecule that clears MUC1-fs from patient cells, from kidneys of knockin mice and from patient kidney organoids. MUC1-fs is trapped in TMED9 cargo receptor-containing vesicles of the early secretory pathway. BRD4780 binds TMED9, releases MUC1-fs, and re-routes it for lysosomal degradation, an effect phenocopied by TMED9 deletion. Our findings reveal BRD4780 as a promising lead for the treatment of MKD and other toxic proteinopathies. Generally, we elucidate a novel mechanism for the entrapment of misfolded proteins by cargo receptors and a strategy for their release and anterograde trafficking to the lysosome.<br /> (Copyright © 2019 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1097-4172
Volume :
178
Issue :
3
Database :
MEDLINE
Journal :
Cell
Publication Type :
Academic Journal
Accession number :
31348885
Full Text :
https://doi.org/10.1016/j.cell.2019.07.002